# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 31 results.
Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting
Last Changed: Dec 13, 2019
First Received: Aug 27, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Camrelizumab
Locations: Sanbo Brain Hospital Capital Medical University, Beijing, China
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Sep 10, 2019
First Received: Sep 10, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): rituximab in combination with methotrexate, cytarabine and dexamethasone
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tisagenlecleucel In Primary CNS Lymphoma
Status: Not yet recruiting
Last Changed: Oct 22, 2019
First Received: Oct 22, 2019
Disease(s): Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
Intervention(s): Tisagenlecleucel
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting
Last Changed: May 01, 2019
First Received: Jul 10, 2018
Disease(s): Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Intervention(s): Ibrutinib, Copanlisib
Locations: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
... and 3 other locations.
Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma
Status: Not yet recruiting
Last Changed: Aug 29, 2019
First Received: Aug 29, 2019
Disease(s): Primary CNS Lymphoma
Intervention(s): Venetoclax, Obinutuzumab
Locations: Klinikum Stuttgart, Stuttgart, Baden-Württemberg, Germany
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
Status: Recruiting
Last Changed: May 24, 2019
First Received: Jun 26, 2018
Disease(s): Primary CNS Lymphoma
Intervention(s): Rituximab, Methotrexate, Cytarabine
Locations: Samsung Medical Center, Seoul, Gangnam-gu,, Korea, Republic of
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL:a Multicenter Phase Ib/II Stuty
Status: Recruiting
Last Changed: Oct 09, 2019
First Received: Oct 09, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Methotrexate, Rituximab, Lenalidomide
Locations: Daobin Zhou, Beijing, Dongcheng District, China
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Jul 03, 2019
Disease(s): Primary CNS Lymphoma, Brain Lymphoma
Intervention(s): A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy
Locations: Chang Gung Memorial Hospital, Taoyuan, Taiwan
Treatment of Primary CNS Lymphoma
Status: Recruiting
Last Changed: Jul 21, 2015
First Received: Oct 10, 2013
Disease(s): Primary CNS Lymphoma (PCNSL)
Intervention(s): HD-MTX-Ara-C regimen, FVD regimen
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL
Status: Not yet recruiting
Last Changed: Aug 26, 2019
First Received: Aug 26, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): IBER salvage chemotherapy followed by ibrutinib maintenance therapy
Locations: Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of